Breast Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Breast Cancer Information Center has current, evidence-based information for you. Get the facts about breast cancer prevention, early detection, treatment, reconstruction, and survivorship, and stay up to date with ongoing breast cancer research that could impact your treatment decisions through our daily cancer news.
Join the conversation! Private, anonymous breast cancer online support community. Login or register here.
A class of drugs known as aromatase inhibitors (AI) commonly used in the management... Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer
The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole)... Metastatic Breast Cancer- Ask the Expert, Your Questions Answered
Ask the Expert session with Memorial Sloan Kettering Cancer Center’s Chau T. Dang,...
By Karen Syrjala, PhD Director of Biobehavioral Sciences and co-director of the Survivorship... Understanding Osteonecrosis of the Jaw
Cancer and its treatment can come with a variety of complications, some more serious... What is Genomics & How is it changing the Management of Cancer
You’ve probably heard of genetic testing for cancer susceptibility, but the more...
Breast Cancer Management
Patients see benefits as cancer care continues to evolve. By Susan Kreimer Donna... Young Survivor Profile: Kirby Jamail
Houston, Texas, native Kirby Jamail was diagnosed with Stage III, triple-negative... Sharing Her Silver Lining
By Diana Price When Hollye Jacobs was diagnosed with breast cancer at 39, her first...
Breast Cancer Clinical Trials
07040 – A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer
NU07B1 – A Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer
98-04 – Phase III Trial of Observation Plus or Minus Tamoxifen VS. RT Plus or Minus Tamoxifen for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast.